SLC16A1 and neoplasm: The analysis showed that the expression of ACAT1, BDH1 and SLC16A1 was significantly higher in bone metastatic samples when compared with the primary tumor site (P = 0.0042, P = 0.0091, and P = 0.0006, respectively) (Fig. S6A).